skip to content
Primary navigation

Ibrance

Drug - IBRANCE™ (palbociclib capsules) [Pfizer]

May 2016

Therapeutic area - Oncology

Approval criteria

  • Patient has a diagnosis of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer AND
  • Ibrance treatment will be in combination with letrozole as initial endocrine based therapy in postmenopausal women OR
  • In combination with fulvestrant in women with disease progression following endocrine therapy

Quantity limit

21 capsules every 28 days

Background information

IBRANCE is a kinase inhibitor indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease.

Questions?

MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top